CHICAGO--(BUSINESS WIRE)-- Sarah Cannon Research Institute (SCRI) today announced an intention to collaborate scientifically with Yale Cancer Center (YCC) and Smilow Cancer Hospital at Yale-New Haven (SCH) to advance cancer research. A formal agreement will follow in the coming weeks.
“SCRI, Yale Cancer Center, and Smilow Cancer Hospital share the goal of improving the treatment of cancer. This collaboration is exciting as it allows each organization to capitalize on their areas of expertise in cancer research,” said Dr. Howard “Skip” A. Burris III, chief medical officer and executive director of drug development for SCRI.
As part of the collaboration, SCRI would meet regularly with clinical investigators from Yale to discuss strategic scientific priorities for certain tumor types and to develop clinical research protocols. Additionally, this collaboration would serve to enhance clinical trial opportunities for patients seeking treatment at both organizations.
“SCRI is the nation’s premier clinical research institute with a strong track record for implementing quality clinical trials. The organization will bring value and opportunities to Yale’s already renowned experience in cancer innovation and care,” said Dr. Thomas Lynch, Jr., director of YCC and physician-in-chief of Smilow Cancer Hospital at Yale-New Haven. “This collaboration will be an example of how three leading, research-driven organizations are putting the best interest of cancer patients first.”
“Bringing together our broad clinical trial expertise with Yale’s drug discovery and translational expertise will make for a unique collaboration unrivaled in the field of cancer research,” said SCRI Chief Executive Officer Dee Anna Smith.
SCRI offers a robust clinical research infrastructure, expansive strategic investigator site network and a drug development program that has conducted more than 80 first-in-man trials. YCC is an National Cancer Institute-designated comprehensive cancer center with a strong background in drug discovery, molecular profiling and translational research through clinical care at Smilow Cancer Hospital. The three organizations bring key scientific and clinical leaders with international prowess to the relationship.
SCRI is a global strategic research organization focusing on advancing therapies and accelerating drug development. It is one of the largest clinical research programs, conducting community-based clinical trials in oncology, cardiology, gastroenterology and other therapeutic areas through affiliations with a network of more than 700 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites.
YCC is one of a select network of 40 comprehensive cancer centers in the country designated by the National Cancer Institute and the only one in Southern New England. Bringing together the resources of Yale-New Haven Hospital and the Yale University School of Medicine, its mission encompasses patient care, research, cancer prevention and control, community outreach and education.
Smilow Cancer Hospital at Yale-New Haven is part of Yale-New Haven Hospital and is affiliated with Yale Cancer Center. Smilow Cancer Hospital, the most comprehensive cancer facility in New England, is a 14-story, 500,000-square-foot cancer hospital, which includes: 168 private inpatient rooms, outpatient multidisciplinary treatment centers, 12 operating rooms, infusion suites, diagnostic imaging services, a floor for children with cancer, a specialized women's cancer center and diagnostic and therapeutic radiology services for children and adults.
Anna Walker, 615-329-7216
KEYWORDS: United Kingdom United States Europe North America Illinois
INDUSTRY KEYWORDS: Health Hospitals Oncology Pharmaceutical Research Science